Related Experiment Video
Updated: Jan 23, 2026

Imaging Dpp Release from a Drosophila Wing Disc
Published on: October 30, 2019
DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General
Dionysis Spanopoulos1, Michael Busse1, Joanne Webb2
1Boehringer Ingelheim Ltd, Berkshire, United Kingdom.
Abstract:
Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting.
Related Concept Videos
Dose-Response Relationship: Selectivity and Specificity
Dipeptidyl Peptidase 4 Inhibitors
Contemporary Psychology
Biopsychology
Biopsychology, also known as biological psychology or behavioral neuroscience, focuses on the biological underpinnings of behavior and mental processes. It...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Steel Manufacturing
During this smelting process, limestone plays a crucial role by forming slag. Slag captures impurities within the molten iron, such...
Dose Size and Dosing Frequency: Determination Methods

